8-KOther Events

Edwards Lifesciences Corp 8-K Report (Feb 3, 2004)

Filed February 3, 2004For Securities:EW

Summary

Edwards Lifesciences Corporation (EW) filed an 8-K report on February 3, 2004, primarily to disclose its financial results for the fourth quarter and the full year ended December 31, 2003. The report itself is brief, with the key investor information contained within the attached press release (Exhibit 99.1). This filing marks the official public dissemination of the company's performance metrics for the preceding fiscal periods, enabling investors to assess the company's financial health and operational achievements. Investors should review the attached press release for detailed financial data, including revenue, profitability, and any forward-looking statements or management commentary on the results. This 8-K serves as a crucial point of reference for understanding Edwards Lifesciences' financial standing as of the end of 2003 and any immediate outlook provided by the company.

Key Highlights

  • 1Filing of an 8-K report by Edwards Lifesciences Corporation on February 3, 2004.
  • 2The report's primary purpose is to disclose financial results for the fourth quarter and full year ended December 31, 2003.
  • 3Key financial details and performance metrics are provided in an attached press release (Exhibit 99.1).
  • 4This filing allows investors to access and analyze the company's reported financial performance.
  • 5The report is an official record of the company's financial outcomes for the specified periods.
  • 6No significant new operational events, material agreements, or executive changes are detailed within the 8-K itself, beyond the financial results announcement.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report Edwards Lifesciences Corporation's financial results for the fourth quarter and the full fiscal year ended December 31, 2003. This information is provided to the public and regulators via an attached press release.

The detailed financial results are contained within Exhibit 99.1, which is a press release dated February 3, 2004, attached to this 8-K filing.

Based on the provided content of the 8-K itself, the filing's focus is solely on the release of financial results. Any significant business developments would be detailed within the press release (Exhibit 99.1), which is not included in this excerpt.

This filing is significant for investors as it provides the official, reported financial performance of Edwards Lifesciences for the year and quarter ending December 31, 2003. Investors can use this data to evaluate the company's profitability, revenue growth, and overall financial health.